The launch of a groundbreaking clinical trial in oncology and the publication of guidance from the US FDA highlight increasing support for the use of adaptive clinical trials in the development of new drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. Adaptive trials receive boost. Nat Rev Drug Discov 9, 345–348 (2010). https://doi.org/10.1038/nrd3174
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3174
This article is cited by
-
Portfolio Decisions in Early Development
Pharmaceutical Medicine (2012)
-
2010 in reflection
Nature Reviews Drug Discovery (2011)